Metropolis Healthcare shares gained over 3% on Monday, with the stock trading at ₹1,960, up 3.33% and gaining ₹63.20 on the NSE. The uptick followed the company's strong Q3 FY26 business update announcement. According to recent market data, the stock had previously surged over 6% marking its biggest intraday gain since October 6, 2025, and reached its highest point since November 6, 2025. The company's market capitalization stands at ₹10,439.80 crore. Recent historical performance shows the stock has gained 5.17% in one day, 5.98% over five days, 4.85% in one month, and 17.83% over six months, though it remains down 0.77% over the past year.
The company delivered a strong 26% year-on-year consolidated revenue growth for the quarter ending December 31. This growth was driven by sustained momentum in preventive and wellness health check-ups under TruHealth, along with a strong increase in specialty testing volumes across both B2C and B2B channels. The company successfully scaled its specialty business across its pan-India network, supported by an expanded Core Diagnostics test menu for high-end specialty testing and continuous in-house innovation. On a standalone basis, revenue grew by approximately 15% year-on-year, supported by higher patient and test volumes. The consolidated growth includes contributions from Core Diagnostics, Scientific Pathology, Dr. Ahuja's Pathology & Imaging Center, and Dr. RS Patil's Ambika Pathology Laboratory.
The TruHealth Wellness and Speciality segments recorded impressive growth of 35% and 33% YoY respectively for Q3FY26. B2B revenue growth accelerated to 37% YoY, driven by addition of wallet share among customers, especially for the specialty segment and higher contribution of B2B business in Core Diagnostics. The B2C segment contributed with an 18% year-on-year revenue increase. On a standalone basis, revenue jumped 15% YoY, primarily led by increased patient count and test volumes, along with a favorable shift in product mix and realizations. For standalone operations, TruHealth Wellness and specialty segments grew 23% and 16% respectively, while B2C revenues witnessed 14% growth and B2B segment rose 16%.
EBITDA margins expanded for the December quarter compared to the previous year, despite being a seasonally weak period for the diagnostic industry. The company highlighted successful integration of all acquisitions, with synergies delivering operational efficiencies and strengthened operating leverage. The integration of recent acquisitions is progressing well, contributing to operational efficiencies and improved profitability. Core Diagnostics' margins are trending in line with estimates and remain similar to Q2 levels, while DAPIC (Dehradun), Scientific (Agra), and Ambika (Kolhapur) continue to outperform the company's average margins. Recent acquisitions have shown margin improvement from breakeven in March to high-single-digit margins.
Metropolis Healthcare maintains its full-year guidance and confirms no new acquisitions are planned for the next 6-9 months as the company focuses on organic growth and integration of recent acquisitions. The company has added approximately 200 collection centres in the first half of FY26 and plans to add another 300 collection centres in H2 FY26, focusing on network expansion in Tier 2 and Tier 3 cities. The company is enhancing specialized testing capabilities, strengthening its TruHealth portfolio, and implementing AI-driven tools for improved efficiency. Management remains confident in its ability to meet stated estimates in H2 FY26 and further build its leadership position nationwide. The management noted that the current update represents a business performance snapshot, with detailed audited financial results for Q3 FY26 to be announced separately after board approval.
